AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7944426
Drug: Postoperative intrahepatic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intrahepatic arterial infusion with Farmorubicin and 5‐FU (i.a group)
Trial: 2976670
Drug: Enoximone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (3 mg/kg oral and 1 mg/kg i.v.)
Trial: 30100052
Drug: Low-moderate epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-moderate epinephrine doses
Trial: 15062137
Drug: Brachytherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachytherapy with supplemental external beam radiation therapy (XRT)
Trial: 15062137
Drug: Brachytherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brachytherapy without supplemental external beam radiation therapy (XRT)
Trial: 1333960
Drug: Urodilatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urodilatin (4 micrograms kg‐1 bw, two high dose intravenous bolus injections at a 30 min interval, n = 6)
Trial: 1333960
Drug: ANF(99‐126) (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANF(99‐126) (4 micrograms kg‐1 bw, same dosing as Urodilatin, n = 6)
Trial: 30915366
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection combined with miniscalpel-needle (MSN) release
Trial: 25040756
Drug: Tramadol 2
RxNorm normalized name: traMADol 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 2 mg·kg(‐1) 6-hourly for up to 5 days
Trial: 25040756
Drug: Placebo 6-hourly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 6-hourly for up to 5 days
Trial: 20025149
Drug: NG‐nitro‐L‐arginine‐methyl‐ester (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG‐nitro‐L‐arginine‐methyl‐ester (1 mg x kg(‐1))
Trial: 15889234
Drug: Metformin (850-2,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850-2,550 mg/day)
Trial: 12485118
Drug: lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 60 mg once a day (qd)
Trial: 12485118
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg twice a day (bid)
Trial: 9787889
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 mg daily
Trial: 7649971
Drug: Higher-dose range
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose range nefazodone (100-600 mg/day)
Trial: 7649971
Drug: Placebo (2-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2-6 capsules per day)
Trial: 7649971
Drug: Lower-dose range
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose range nefazodone (50-300 mg/day)
Trial: 1221110
Drug: Ethanol (0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.67 g/kg body weight) ingested at 0700
Trial: 1221110
Drug: Ethanol (0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.67 g/kg body weight) ingested at 1100
Trial: 1221110
Drug: Ethanol (0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.67 g/kg body weight) ingested at 1900
Trial: 1221110
Drug: Ethanol (0.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.67 g/kg body weight) ingested at 2300
Trial: 17984346
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rifampin and azithromycin
Trial: 7525633
Drug: 0.02 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg/kg BW.day recombinant human GH (rhGH)
Trial: 3037812
Drug: RIT 4256
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4256 vaccine in adults
Trial: 3037812
Drug: RIT 4256
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4256 vaccine in 6-month-old children
Trial: 3037812
Drug: RIT 4256
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4256 vaccine in newborn infants
Trial: 3037812
Drug: RIT 4237
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, RIT-4385 strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIT 4237 vaccine in newborn infants
Trial: 3037812
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of RIT 4256 and RIT 4237 vaccines
Trial: 30260251
Drug: 3 mL/kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL/kg of 3% HS (group L)
Trial: 30260251
Drug: 5 mL/kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL/kg of 3% HS (group H)
Trial: 27165280
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg and 5 mg
Trial: 20724648
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg alogliptin plus 30 mg pioglitazone (A25+P30)
Trial: 20724648
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg alogliptin (A25)
Trial: 20724648
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pioglitazone (P30)
Trial: 18772723
Drug: Viscous marketed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Viscous marketed artificial tear formulations (test formulation)
Trial: 7674700
Drug: Ketoprofen solution
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen solution (25 mg)
Trial: 7674700
Drug: Ketoprofen tablet
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen tablet (2.5 mg)
Trial: 7012668
Drug: Allopurinol therapy
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol therapy
Trial: 31104280
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg netupitant/0.5 mg palonosetron
Trial: 24570327
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) intravenous infusion of 20 ng/kg/min for 6 hours before and after contrast media administration
Trial: 24570327
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution for routine hydration (control group)
Trial: 22024226
Drug: PEG-IFN a-2b/RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-IFN a-2b/RBV therapy (Secondary IFN group)
Trial: 17223306
Drug: Continuous iliofascial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous iliofascial nerve sheath block (KT group) with 30 ml of ropivacaïne 4.75 mg/ml and 14 mg/h of ropivacaïne 2 mg/ml for 48 hours
Trial: 16753936
Drug: Aortic valve-sparing
RxNorm normalized name: VALVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aortic valve-sparing operations (David I reimplantation technique, Gel-weave Valsalva graft)
Trial: 12648174
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg misoprostol initially then a further identical dose 6 h later
Trial: 12648174
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dinoprostone initially followed by 1 mg 6 h later
Trial: 12648174
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg dinoprostone
Trial: 8842782
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg initial dose followed by 20 mg tid for 5 days)
Trial: 1495860
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 1,000 micrograms daily
Trial: 6406654
Drug: L-carnitine IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine IV, 10 mg/kg . day
Trial: 26902504
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone furoate (FF) and vilanterol (VI) combination therapy
Trial: 26902504
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone furoate (FF)
Trial: 26902504
Drug: Inhaled vilanterol
RxNorm normalized name: fluticasone / vilanterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled vilanterol (VI)
Trial: 15692889
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone for one month (first week) and topical fluormetalone for the next three weeks
Trial: 15692889
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone for one week
Trial: 7028533
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (25 mg for ages 2-5 years; 50 mg for ages 6-10 years)
Trial: 25614155
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg/day plus Serenoa repens 320 mg/day
Trial: 25614155
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg/day only
Trial: 23617610
Drug: Nucleus(®) cochlear
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus(®) cochlear implant fitting suite
Trial: 21508862
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment (2 weeks and 4 weeks duration)
Trial: 19825324
Drug: Paliperidone immediate-release
RxNorm normalized name: paliperidone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone immediate-release (IR) 1 mg dose
Trial: 16869814
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of cefotaxime (2 g over 24 h plus a loading dose of 1 g)
Trial: 16869814
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of cefotaxime (1 g three times daily)
Trial: 15200652
Drug: Ropivacaine (0.4%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.4%, 2 mg x kg(‐1))
Trial: 15200652
Drug: Ropivacaine (0.2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.2%, 1 mg x kg(‐1)) plus ketamine (0.25 mg x kg(‐1))
Trial: 15200652
Drug: Ropivacaine (0.2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.2%, 1 mg x kg(‐1)) plus tramadol (1 mg x kg(‐1))
Trial: 9549662
Drug: Metrifonate (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (LD = 1.5 mg/kg, MD = 0.25 mg/kg)
Trial: 9549662
Drug: Metrifonate (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (LD = 2.5 mg/kg, MD = 0.40 mg/kg)
Trial: 9549662
Drug: Metrifonate (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (LD = 4.0 mg/kg, MD = 0.65 mg/kg)
Trial: 9549662
Drug: Metrifonate (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (LD = 4.0 mg/kg, MD = 1.0 mg/kg)
Trial: 9549662
Drug: Metrifonate (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (highest doses)
Trial: 2731781
Drug: Ticlopidine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 500 mg/day
Trial: 27939089
Drug: Intervention A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention A: 12-session treatment program including discussion of low back pain experience, graded sensory training, graded motor imagery training, and functional movement training.
Trial: 27939089
Drug: Intervention B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention B: 12-session treatment program including discussion of low back pain experience, transcranial direct current stimulation, cranial electrical stimulation, low-intensity laser therapy, and pulsed electromagnetic energy.
Trial: 21372302
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day simvastatin
Trial: 18669979
Drug: ezetimibe/simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20 mg/day
Trial: 22088245
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg/d) plus Irbesartan (150 mg/d)
Trial: 22088245
Drug: Felodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (5 mg/d) plus Metoprolol (47.5 mg/d)
Trial: 7636648
Drug: DTaP vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP vaccine (booster dose)
Trial: 2794204
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate at 40 meq/L
Trial: 2794204
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate at 100 meq/L
Trial: 2794204
Drug: 0 meq/L
RxNorm normalized name: Sodium Chloride 0.9% with Potassium Chloride 20 mEq/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 meq/L sodium bicarbonate
Trial: 2794204
Drug: 10 meq/L
RxNorm normalized name: Dextrose 5% and Water with Potassium Chloride 10 mEq/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 meq/L sodium bicarbonate
Trial: 21334626
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (nutrition education, exercise therapy, psychological care)
Trial: 15145924
Drug: Sildenafil (Sil)
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil (Sil) 3 x 40 mg/day
Trial: 8062500
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (30 mg every 6 hours) with hydrochlorothiazide/amiloride (50 mg/5 mg daily)
Trial: 8062500
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (30 mg every 6 hours) with placebo
Trial: 30562225
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration anaesthesia (LIA) with 150 ml of ropivacaine 0.2% at the end of surgery.
Trial: 30562225
Drug: Single-shot sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-shot sciatic nerve block with 20 ml of ropivacaine 0.75% and adductor canal block with catheter infusion of ropivacaine 0.2% at 6 ml/h for less than 4 days.
Trial: 27988180
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mix 25
Trial: 21415269
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin and autologous HCT in favorable-risk AML
Trial: 21415269
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin and autologous HCT in intermediate-risk AML
Trial: 17299489
Drug: 0-60 g
RxNorm normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0-60 g of retrograded resistant maltodextrins (RRM)
Trial: 17299489
Drug: Gradually increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradually increasing doses of RRM over 21 days
Trial: 17299489
Drug: >60 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: >60 g RRM
Trial: 14734593
Drug: Ranolazine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranolazine (750 mg or 1000 mg, twice daily)
Trial: 28286115
Drug: Augmented renal
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented renal clearance (ARC) patients receiving β-lactam therapy
Trial: 28286115
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without augmented renal clearance (no ARC) receiving β-lactam therapy
Trial: 28286115
Drug: Both ARC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ARC and no ARC patients receiving β-lactam therapy
Trial: 23295775
Drug: Collaborative group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative group intervention (10 weekly group sessions and 2 booster meetings)
Trial: 21867621
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HD-MTX) - CF + VDT protocol
Trial: 12173945
Drug: 6 g;pdd(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g;pdd(‐1) of CLA with 3 g;pdd(‐1) of fatty acids for 28 days
Trial: 12173945
Drug: 9 g;pdd(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g;pdd(‐1) of an olive oil placebo for 28 days
Trial: 2200896
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg.kg‐1
Trial: 8597965
Drug: Midazolam 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.4 mg.kg‐1
Trial: 8597965
Drug: Midazolam 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.6 mg.kg‐1
Trial: 4820642
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and fresh frozen plasma
Trial: 22985565
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg once a year)
Trial: 22985565
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Vitamin D3 and Caltrate daily for a year)
Trial: 18570599
Drug: Fexofenadine 180
RxNorm normalized name: fexofenadine 180 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 180 mg once each morning
Trial: 18570599
Drug: Chlorpheniramine 6
RxNorm normalized name: carbetapentane-chlorpheniramine 60 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 6 mg (2 mg in the morning and 4 mg after 12 h)
Trial: 15912655
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1,000 mg/day)
Trial: 12478147
Drug: Re-dosing based
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-dosing based on serum testosterone
Trial: 10718909
Drug: Insulin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.15 U/kg)
Trial: 10718909
Drug: Naloxone and
RxNorm normalized name: Naloxone and oxycodone only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone and vasopressin in combination
Trial: 8794436
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg micronized 17 beta‐estradiol continuously
Trial: 8794436
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg micronized 17 beta‐estradiol continuously
Trial: 8794436
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg and 2 mg 17 beta‐estradiol alternating every 42 days
Trial: 1352247
Drug: Azelastine 2
RxNorm normalized name: azelastine 2.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 2 mg b.d. p.o. for 10 days
Trial: 6466017
Drug: Sodium restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restriction (40 mEq of sodium daily)
Trial: 30623236
Drug: IA-HA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-HA (2 ml/week, for 3 weeks)
Trial: 30623236
Drug: IA-CS (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-CS (1 ml)
Trial: 30623236
Drug: IA-PRP (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-PRP (4 ml, 3 times, every 3 weeks)
Trial: 29224460
Drug: Rocking chair
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocking chair therapy (vestibular stimulation)
Trial: 27132044
Drug: Citalopram (30mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (30mg, oral)